Seroprevalence of ANTI-SARS-CoV-2 antibodies in patients with inflammatory bowel disease.

ABSTRACT: Patients with inflammatory bowel disease (IBD) treated with biologic and/or immunosuppressant drugs are at increased risk for opportunistic infections. Seroprevalence studies can confirm the diagnosis of SARS-CoV-2 infections as well as the associated risk factors. This is a descriptive study which primary endpoints were to highlight the prevalence of SARS-CoV-2 antibodies in a cohort of IBD patients in March 2021, and to analyze seroconversion in patients with known COVID-19 infection and its relationship with IBD treatments. Patients filled in a questionnaire about symptoms of COVID-19 infection and clinical information about their IBD. All included patients were tested for SARS-CoV-2 antibodies. 392 patients were included. Among patients with clinical infection, 69 patients (17,65%) wer

SUBMITTER: Martin-Arranz MD 

PROVIDER: S-EPMC10148621 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature